- Home
- Publications
- Publication Search
- Publication Details
Title
An update on first line therapies for metastatic breast cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 19, Issue 3, Pages 243-252
Publisher
Informa UK Limited
Online
2018-01-16
DOI
10.1080/14656566.2018.1425680
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting triple negative breast cancer with histone deacetylase inhibitors
- (2017) Palma Fedele et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order
- (2016) Edith A. Perez DRUG RESISTANCE UPDATES
- Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
- (2016) Gil Awada et al. EXPERT OPINION ON EMERGING DRUGS
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
- (2016) Ahmad Awada et al. JAMA Oncology
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- (2015) Leisha A. Emens et al. CANCER RESEARCH
- Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)
- (2015) Andrew Tutt et al. CANCER RESEARCH
- Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
- (2015) Rita Nanda et al. CANCER RESEARCH
- Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
- (2015) Palma Fedele et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.
- (2015) Chris Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
- (2015) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer, Version 1.2016
- (2015) William J. Gradishar et al. Journal of the National Comprehensive Cancer Network
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
- (2015) Xi-Chun Hu et al. LANCET ONCOLOGY
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Global Burden of Cancer 2013
- (2015) Christina Fitzmaurice et al. JAMA Oncology
- Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
- (2014) Jung Eun Choi et al. ANNALS OF SURGICAL ONCOLOGY
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Ann H. Partridge et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
- (2014) Hatem Soliman et al. PLoS One
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis
- (2013) F. E. Vera-Badillo et al. JNCI-Journal of the National Cancer Institute
- Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer†
- (2012) Y. Fan et al. ANNALS OF ONCOLOGY
- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer
- (2012) Shaheenah Dawood et al. CANCER
- Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
- (2012) Nancy U. Lin et al. CANCER
- Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?
- (2012) Palma Fedele et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
- (2012) José R. Rossari et al. Journal of Oncology
- The role of chemotherapy and targeted agents in patients with metastatic breast cancer
- (2011) Stephen R.D. Johnston EUROPEAN JOURNAL OF CANCER
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
- (2011) John M.S. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- Receptors, Associations, and Risk Factor Differences by Breast Cancer Subtypes: Positive or Negative?
- (2011) L. Bernstein et al. JNCI-Journal of the National Cancer Institute
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) F. Cardoso et al. ANNALS OF ONCOLOGY
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
- (2010) Rob Riemsma et al. BREAST CANCER RESEARCH AND TREATMENT
- Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo
- (2010) Pierfrancesco Tassone et al. CANCER BIOLOGY & THERAPY
- Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel
- (2010) Fausto Petrelli et al. EXPERT OPINION ON PHARMACOTHERAPY
- Acquired endocrine resistance in breast cancer: implications for tumour metastasis
- (2010) Edd Hayes Frontiers in Bioscience-Landmark
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
- (2010) O. Pagani et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- Therapeutic options for metastatic breast cancer
- (2009) Patrick G Morris et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
- (2009) M. Santarosa et al. MOLECULAR CANCER THERAPEUTICS
- The prognostic importance of triple negative breast carcinoma
- (2008) Hakan Mersin et al. BREAST
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
- (2008) Robert J. Paridaens et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More